Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration.
At Two Labs, our mission is to improve patients’ quality of life by delivering innovative trade and commercialization services to pharmaceutical manufacturers.
We recently notified our clients and partners of several regulatory changes that will affect manufacturers and wholesalers doing business in Minnesota. In May 2019, Minnesota Governor Tim Walz signed House Bill 400, which created an Opioid Stewardship Advisory Council to confront the opioid addiction crisis and overdose epidemic.
In the pharmaceutical industry, state licensing requirements can change at a moment’s notice. Though no central “hub” exists listing all licensing updates for each state, our team of experts works with state boards on a routine basis to track all license requirement updates.
The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving.
With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021.
By now, you’ve probably heard of the DSCSA. Since its passing in 2013, the act has been the talk of the industry as it continues to reshape the distribution landscape. However, because of the staggered roll out, varied enforcement dates, and multiple moving pieces, the DSCSA can be tricky. To help you keep track of the most important changes, we have mapped out the key things to know about the DSCSA in 2018 and beyond.
It was great meeting all of you who were able to stop by our booth in Glasgow! It was a great experience to present our findings to the industry innovators at ISPOR.
